Ironwood Pharmaceuticals, Inc. · Cambridge, MA United States (NASDAQ: IRWD)
| 320 Bent St. | Phone: 617-621-7722 |
| Cambridge, MA | Fax: 617-494-0908 |
| 02141 | |
| United States | 
Map This Company |
Ironwood Pharmaceuticals, Inc. Rankings
More Companies in These Related Industries: Administrative Support ServicesCompany Description
Ironwood Pharmaceuticals (formerly Microbia) is tackling the dreaded IBS. The company is developing its own internally discovered gastrointestinal drugs, namely lead candidate linaclotide, a compound in later-stage clinical trials for the treatment of irritable bowel syndrome. Linaclotide acts to reduce abdominal pain, discomfort, bloating, and constipation associated with IBS. The product is being co-developed with
Ironwood Pharmaceuticals, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: IRWD Headquarters |
|---|---|
| Fiscal Year-End | December |
| Employees | 217 |
Executives
28 executives listed for Ironwood Pharmaceuticals, Inc.'s Cambridge, MA location.
| Chairman | Joseph Cook | |
|---|---|---|
| CEO and Director | Peter Hecht | |
| SVP, COO, and CFO | Michael Higgins |